COLLEGIUM PHARMACEUTICAL, INC
For the period ended May 15, 2025. Filed Mar 28, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 15, 2025 · Filed Mar 28, 2025
Contents
2025 PROXY STATEMENT SUMMARY
This proxy statement is furnished to shareholders of Collegium Pharmaceutical, Inc. in connection with the solicitation of proxies by our board of directors (the “board”). In this proxy statement, unless expressly stated otherwise or the context otherwise requires, the use of “Collegium,” the “Company,” “our,” “we” or “us” refers to Collegium Pharmaceutical, Inc. and its subsidiaries. The Notice will first be mailed to shareholders on or about April 2, 2025. This summary highlights information contained elsewhere in this proxy statement. This summary does not contain all the information you should consider. You should read the entire proxy statement carefully before voting.
2025 Annual Meeting
| When | | Record Date | ||
| | Thursday, May 15, 20258:30 a.m. Eastern Time | | | Only shareholders of record at the close of business on March 25, 2025 are entitled to notice of, and to vote at, the 2025 Annual Meeting of Shareholders (the “Annual Meeting”) or any adjournment thereof. |
|---|---|---|---|---|
| Where | ||||
| | www.meetnow.global/MZQSZJF | | | |
| | | | | |
|---|---|---|---|---|
| Item of Business · Board Recommendation · See Page | ||||
| 1 | To elect eight director nominees, each to serve for a one-year term extending until our 2025 Annual Meeting of Shareholders and their successors are duly elected and qualified | FOR each nominee | 13 | |
| 2 | To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement | FOR | 41 | |
| 3 | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers | FOR “One Year” | 84 | |
| 4 | To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 | FOR | 85 | |
| 5 | To approve the Collegium Pharmaceutical, Inc. 2025 Equity Incentive Plan | FOR | 88 | |
| 6 | To transact any other business properly brought before the Annual Meeting | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.